TARS Q1 2021 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

TARSTarsus Pharmaceuticals, Inc.

$3B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$33M

Gross Profit

$32M96.1% margin

Operating Income

$11M32.0% margin

Net Income

$10M30.8% margin

EPS (Diluted)

$0.47

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$194M

Total Liabilities

$11M

Stockholders' Equity

$183M

Cash & Equivalents

$156M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$33M	$0	—
Gross Profit	$32M	$0	—
Operating Income	$11M	-$2M	+605.9%
Net Income	$10M	-$2M	+625.6%

Revenue Segments

License and Service

$33M96%

License And Collaboration

$1M4%

Collaboration

$121,0000%